Data Year:

For its 2025 fiscal year, TREACE MEDIC CNCPTS INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In MFG Durable industry
Mark L. Hair
Chief Financial Officer
Total Compensation $5,157,046 View details Pay Rank By Title In MFG Durable industry #110 View more
John T. Treace
Chief Executive Officer, Founder and Board Chair
Total Compensation $5,405,190 View details Pay Rank By Title In MFG Durable industry #387 View more
Sean F. Scanlan
Chief Innovation Officer
Total Compensation $2,310,895 View details Pay Rank By Title In MFG Durable industry #94 View more
Gaetano M. Guglielmino
Chief Commercial Officer
Total Compensation $468,536 View details Pay Rank By Title In MFG Durable industry #197 View more
Scot M. Elder
Chief Legal & Compliance Officer, Corporate Secretary
Total Compensation $2,123,983 View details Pay Rank By Title In MFG Durable industry #88 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at TREACE MEDIC CNCPTS INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. TREACE MEDIC CNCPTS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. TREACE MEDIC CNCPTS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Mark L. Hair
Chief Financial Officer
Total Cash $509,959 Equity $4,632,250 Other $14,837 $5,157,046
John T. Treace
Chief Executive Officer, Founder and Board Chair
Total Cash $755,353 Equity $4,635,000 Other $14,837 $5,405,190
Sean F. Scanlan
Chief Innovation Officer
Total Cash $446,370 Equity $1,849,688 Other $14,837 $2,310,895
Gaetano M. Guglielmino
Chief Commercial Officer
Total Cash $440,000 Equity $0 Other $28,536 $468,536
Scot M. Elder
Chief Legal & Compliance Officer, Corporate Secretary
Total Cash $432,096 Equity $1,677,050 Other $14,837 $2,123,983
For its 2025 fiscal year, TREACE MEDIC CNCPTS INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
John T. Treace CEO Pay $5,405,190 Median Employee Pay $153,425 CEO Pay Ratio 35:1
For its 2024 fiscal year, TREACE MEDIC CNCPTS INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Deepti Jain Total Cash $224,564
Elizabeth S. Hanna Total Cash $214,674
James T. Treace Total Cash $99,780
Jane E. Kiernan Total Cash $204,894
John K. Bakewell Total Cash $224,784
Lance A. Berry Total Cash $205,004
Lawrence W. Hamilton Total Cash $224,784
Richard W. Mott Total Cash $225,727
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.